Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cancer Vaccines01:30

Cancer Vaccines

854
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
854
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

17.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Conjugated Proteins02:50

Conjugated Proteins

25.0K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
25.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Vaccinations01:51

Vaccinations

50.5K
Overview
50.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

mRNA-based influenza vaccine expands the B cell response breadth in humans.

Nature immunology·2026
Same author

Hemagglutination inhibition and alternate serologic responses following Influenza A(H3N2) virus infection.

medRxiv : the preprint server for health sciences·2026
Same author

Local B cell immunity and durable memory after live-attenuated influenza intranasal vaccination of humans.

Science translational medicine·2026
Same author

B lymphocyte protein factories produced by hematopoietic stem cell gene editing.

Science (New York, N.Y.)·2026
Same author

Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies.

mBio·2026
Same author

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.

Nature microbiology·2026
Same journal

Daily briefing: 'Cyborg' cockroaches breathe underwater with printed suit.

Nature·2026
Same journal

China boosts prestigious grants for young scientists - will it ease competition?

Nature·2026
Same journal

Incoming US science academy chief vows to 'double down' on research.

Nature·2026
Same journal

Author Correction: Synthesis of enantioenriched atropisomers by biocatalytic deracemization.

Nature·2026
Same journal

Electrodeposited self-assembled molecules for perovskite photovoltaics.

Nature·2026
Same journal

Neutrino's nursery found: the 'Shadow Blaster'.

Nature·2026
関連記事をすべて見る

関連する実験動画

Updated: Dec 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

開発中のSARS-CoV-2ワクチン

Florian Krammer1

  • 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.

Nature
|September 23, 2020
PubMed
まとめ
この要約は機械生成です。

深刻な急性呼吸器症候群コロナウイルス2 (SARS-CoV-2) に対するワクチンの開発は急速に進んでいます. 初期試験データは,安全で効果的な新型コロナウイルス病 2019 (COVID-19) ワクチンがすぐに利用可能であることを示唆しています.

さらに関連する動画

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.3K
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

5.0K

関連する実験動画

Last Updated: Dec 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.3K
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

5.0K

科学分野:

  • ウイルス学
  • 免疫学
  • ワクチン学

背景:

  • 2019年末に重症急性呼吸器症候群コロナウイルス2 (SARS-CoV-2) が発生し,2019年のコロナウイルス病 (COVID-19) パンデミックを引き起こした.
  • COVID-19が公衆衛生,経済,社会に及ぼす世界的な影響を軽減するために,ワクチンが不可欠です.

研究 の 目的:

  • SARS-CoV-2を標的としたワクチンの進行中の開発に関する包括的なレビューを提供すること.
  • ワクチンの開発の速度と進歩を評価する

主な方法:

  • 2020年1月上旬にSARS-CoV-2の遺伝子配列が公開された後に開始されたワクチン開発イニシアチブのレビュー.
  • I,II,III段階を含む進行中の臨床試験のデータの分析.

主要な成果:

  • 現在,180種類以上のSARS-CoV-2ワクチン候補が開発段階にある.
  • ステージIとステージIIの試験データは,多くの候補者に対して利用可能であり,多くはステージIIIの試験に進んでいます.
  • 開発のスピードは前例のないもので,第1段階試験は2020年3月に開始されます.

結論:

  • 現在のデータは,有効で安全なSARS-CoV-2ワクチンが数カ月以内に利用可能になる可能性が高いことを示しています.
  • ワクチン開発のタイムラインの加速は,COVID-19の流行を制御するための希望を提供します.